Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Chemo-immunotherapy is the first-line standard of care for patients with PD-L1 positive metastatic triple-negative breast cancer (mTNBC). SYNERGY (NCT03616886) is a dose-finding phase I and a randomized phase II, open-label trial evaluating if targeting the immunosuppressive adenosine pathway can en...

Descripción completa

Detalles Bibliográficos
Autores principales: Buisseret, Laurence, Loirat, Delphine, Aftimos, Philippe, Maurer, Christian, Punie, Kevin, Debien, Véronique, Kristanto, Paulus, Eiger, Daniel, Goncalves, Anthony, Ghiringhelli, François, Taylor, Donatienne, Clatot, Florent, Van den Mooter, Tom, Ferrero, Jean-Marc, Bonnefoi, Hervé, Canon, Jean-Luc, Duhoux, Francois P., Mansi, Laura, Poncin, Renaud, Barthélémy, Philippe, Isambert, Nicolas, Denis, Zoë, Catteau, Xavier, Salgado, Roberto, Agostinetto, Elisa, de Azambuja, Evandro, Rothé, Françoise, Craciun, Ligia, Venet, David, Romano, Emanuela, Stagg, John, Paesmans, Marianne, Larsimont, Denis, Sotiriou, Christos, Ignatiadis, Michail, Piccart-Gebhart, Martine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622534/
https://www.ncbi.nlm.nih.gov/pubmed/37919269
http://dx.doi.org/10.1038/s41467-023-42744-y

Ejemplares similares

Ejemplares similares